Literature DB >> 10383635

Long-term effects of methylprednisolone following transection of adult rat spinal cord.

M Oudega1, C G Vargas, A B Weber, N Kleitman, M B Bunge.   

Abstract

Clinically, high-dose treatment with the glucocorticosteroid, methylprednisolone (MP), within 8 h after spinal cord injury, has been shown to improve neurological recovery. The current standard of care is to administer MP as a bolus of 30 mg/kg followed by a 23-h infusion of 5.4 mg/kg/h to spinal cord injured patients. To better understand the role of MP in neuroprotection, we have studied how MP administration affects macrophage accumulation, tissue loss, and axonal dieback at 1, 2, 4 and 8 weeks after a complete transection of the eighth thoracic spinal cord in the adult rat. A 30 mg/kg dose of MP was administered intravenously at 5 min, and 2 and 4 h after injury. The number of ED1 (antibody against microglia/macrophages) -positive cells was quantified in a 500-micrometer-wide strip of tissue directly adjacent and parallel to the transection. At all time points, MP treatment led to a significant decrease in the number of ED1-positive cells in both rostral and caudal stumps. Over the 2-month post-transection period, the average MP-induced reduction in the number of ED1-positive cells was 82% in the rostral cord stump and 66% in the caudal stump. Using a computerized image analysis system, it was observed that MP treatment resulted in a significant reduction in tissue loss in both cord stumps at 2, 4 and 8 week post-injury. Over the 2-month post-lesion period, the average MP-induced reduction in tissue loss in the caudal cord stump was higher than that in the rostral stump; 48 versus 37%, respectively. Immunostaining for neurofilaments and growth-associated protein-43 (GAP-43) revealed the presence of numerous axons near and in the lesion site. Anterograde neuronal tracing with biotinylated dextran amine showed that, in MP-treated animals, dieback of vestibulospinal fibres, but not of corticospinal fibres, was significantly diminished at all time points studied. In addition, with MP administration, 1 and 2 weeks after injury, an increase in the number of vestibulospinal fibres was found at 1 and 2 mm from the transection, suggesting transient regenerative sprouting of these fibres. The results demonstrate that treatment with MP shortly after spinal cord transection in the adult rat led to a long-term reduction of ED1-positive cells and spinal tissue loss, reduced dieback of vestibulospinal fibres, and a transient sprouting of vestibulospinal fibres near the lesion at 1 and 2 weeks post-lesion. The possible relationships between the inflammatory changes, spinal tissue sparing, and axonal survival and sprouting are complex and need to be further explored.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383635     DOI: 10.1046/j.1460-9568.1999.00666.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  24 in total

1.  A role for complement in the rejection of porcine ventral mesencephalic xenografts in a rat model of Parkinson's disease.

Authors:  R A Barker; E Ratcliffe; M McLaughlin; A Richards; S B Dunnett
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

2.  Protective effect of a new hypothalamic peptide against cobra venom and trauma-induced neuronal injury.

Authors:  A A Galoyan; J S Sarkissian; T K Kipriyan; E J Sarkissian; E A Chavushyan; R M Sulkhanyan; I B Meliksetyan; S S Abrahamyan; Z A Avetisyan; N A Otieva
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

Review 3.  Neurotrophic factors, cellular bridges and gene therapy for spinal cord injury.

Authors:  L L Jones; M Oudega; M B Bunge; M H Tuszynski
Journal:  J Physiol       Date:  2001-05-15       Impact factor: 5.182

Review 4.  Human cellular inflammation in the pathology of acute cerebral ischaemia.

Authors:  C J S Price; E A Warburton; D K Menon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-11       Impact factor: 10.154

5.  Macro-architectures in spinal cord scaffold implants influence regeneration.

Authors:  Darice Y Wong; Jean-Christophe Leveque; Hunter Brumblay; Paul H Krebsbach; Scott J Hollister; Frank Lamarca
Journal:  J Neurotrauma       Date:  2008-08       Impact factor: 5.269

Review 6.  Neuroprotection and acute spinal cord injury: a reappraisal.

Authors:  Edward D Hall; Joe E Springer
Journal:  NeuroRx       Date:  2004-01

7.  Consequences of neurite transection in vitro.

Authors:  Nurettin Cengiz; Gürkan Oztürk; Ender Erdoğan; Aydın Him; Elif Kaval Oğuz
Journal:  J Neurotrauma       Date:  2012-09-27       Impact factor: 5.269

8.  Apparent diffusion coefficients in spinal cord transplants and surrounding white matter correlate with degree of axonal dieback after injury in rats.

Authors:  Eric D Schwartz; Chih-Liang Chin; Jed S Shumsky; Abbas F Jawad; B Kooper Brown; Suzanne Wehrli; Alan Tessler; Marion Murray; David B Hackney
Journal:  AJNR Am J Neuroradiol       Date:  2005-01       Impact factor: 3.825

9.  Effect of combined treatment with methylprednisolone and soluble Nogo-66 receptor after rat spinal cord injury.

Authors:  Benxiu Ji; Mingwei Li; Stephane Budel; R Blake Pepinsky; Lee Walus; Thomas M Engber; Stephen M Strittmatter; Jane K Relton
Journal:  Eur J Neurosci       Date:  2005-08       Impact factor: 3.386

Review 10.  Nanoparticle-mediated local delivery of Methylprednisolone after spinal cord injury.

Authors:  Young-tae Kim; Jon-Michael Caldwell; Ravi V Bellamkonda
Journal:  Biomaterials       Date:  2009-01-30       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.